Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.

Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL 3rd, Fiellin DA, Justice AC, Tate JP.

Ann Epidemiol. 2018 Aug 23. pii: S1047-2797(17)31045-1. doi: 10.1016/j.annepidem.2018.08.007. [Epub ahead of print]

PMID:
30195616
2.

XDR tuberculosis in South Africa: genomic evidence supporting transmission in communities.

Auld SC, Sarita Shah N, Mathema B, Brown TS, Ismail N, Omar SV, Brust JCM, Nelson KN, Allana S, Campbell A, Mlisana K, Moodley P, Gandhi NR.

Eur Respir J. 2018 Aug 16. pii: 1800246. doi: 10.1183/13993003.00246-2018. [Epub ahead of print]

PMID:
30115614
3.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770-18. doi: 10.1128/AAC.00770-18. [Epub ahead of print]

PMID:
30012767
4.

Spatial Patterns of Extensively drug-resistant Tuberculosis (XDR-tuberculosis) transmission in KwaZulu-Natal, South Africa.

Nelson KN, Shah NS, Mathema B, Ismail N, Brust JCM, Brown TS, Auld SC, Omar SV, Morris N, Campbell A, Allana S, Moodley P, Mlisana K, Gandhi NR.

J Infect Dis. 2018 Jun 28. doi: 10.1093/infdis/jiy394. [Epub ahead of print]

PMID:
29961879
5.

Use of Multiple Imputation to Estimate the Proportion of Respiratory Virus Detections Among Patients Hospitalized With Community-Acquired Pneumonia.

Bozio CH, Flanders WD, Finelli L, Bramley AM, Reed C, Gandhi NR, Vidal JE, Erdman D, Levine MZ, Lindstrom S, Ampofo K, Arnold SR, Self WH, Williams DJ, Grijalva CG, Anderson EJ, McCullers JA, Edwards KM, Pavia AT, Wunderink RG, Jain S.

Open Forum Infect Dis. 2018 Mar 16;5(4):ofy061. doi: 10.1093/ofid/ofy061. eCollection 2018 Apr.

6.

Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis.

Auld SC, Shah NS, Cohen T, Martinson NA, Gandhi NR.

Respirology. 2018 Jun 5. doi: 10.1111/resp.13333. [Epub ahead of print] Review.

7.

A dual purpose for household contact investigations: preventing TB disease and improving diabetes outcomes.

Magee MJ, Gandhi NR, Kornfeld H.

Int J Tuberc Lung Dis. 2018 Jun 1;22(6):594-595. doi: 10.5588/ijtld.18.0262. No abstract available.

PMID:
29862941
8.

A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human Mycobacterium tuberculosis Infection.

Whatney WE, Gandhi NR, Lindestam Arlehamn CS, Nizam A, Wu H, Quezada MJ, Campbell A, Allana S, Kabongo MM, Khayumbi J, Muchiri B, Ongalo J, Tonui J, Sasser LE, Fergus TJ, Ouma GS, Ouma SG, Beck AA, Mulligan MJ, Oladele A, Kaushal D, Cain KP, Waller L, Blumberg HM, Altman JD, Ernst JD, Rengarajan J, Day CL; TBRU-ASTRa Study Group.

J Immunol. 2018 Apr 15;200(8):3008-3019. doi: 10.4049/jimmunol.1701737. Epub 2018 Mar 14.

PMID:
29540577
9.

Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.

Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR.

Clin Infect Dis. 2018 Apr 3;66(8):1246-1253. doi: 10.1093/cid/cix1125.

PMID:
29293906
10.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

11.

Tuberculosis Infectiousness and Host Susceptibility.

Turner RD, Chiu C, Churchyard GJ, Esmail H, Lewinsohn DM, Gandhi NR, Fennelly KP.

J Infect Dis. 2017 Nov 3;216(suppl_6):S636-S643. doi: 10.1093/infdis/jix361. Review.

PMID:
29112746
12.

Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?

Auld SC, Kasmar AG, Dowdy DW, Mathema B, Gandhi NR, Churchyard GJ, Rustomjee R, Shah NS.

J Infect Dis. 2017 Nov 3;216(suppl_6):S662-S668. doi: 10.1093/infdis/jix353. Review.

PMID:
29112744
13.

Spatial distribution of extensively drug-resistant tuberculosis (XDR TB) patients in KwaZulu-Natal, South Africa.

Kapwata T, Morris N, Campbell A, Mthiyane T, Mpangase P, Nelson KN, Allana S, Brust JCM, Moodley P, Mlisana K, Gandhi NR, Shah NS.

PLoS One. 2017 Oct 13;12(10):e0181797. doi: 10.1371/journal.pone.0181797. eCollection 2017.

14.

Polymorphisms in the vitamin D receptor gene are associated with reduced rate of sputum culture conversion in multidrug-resistant tuberculosis patients in South Africa.

Magee MJ, Sun YV, Brust JCM, Shah NS, Ning Y, Allana S, Campbell A, Hui Q, Mlisana K, Moodley P, Gandhi NR.

PLoS One. 2017 Jul 10;12(7):e0180916. doi: 10.1371/journal.pone.0180916. eCollection 2017.

15.

Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.

Bablishvili N, Tukvadze N, Shashkina E, Mathema B, Gandhi NR, Blumberg HM, Kempker RR.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01921-16. doi: 10.1128/AAC.01921-16. Print 2017 Sep.

16.

Sociodemographic and Clinical Risk Factors Associated With Tuberculosis Mortality in the United States, 2009-2013.

Hannah HA, Miramontes R, Gandhi NR.

Public Health Rep. 2017 May/Jun;132(3):366-375. doi: 10.1177/0033354917698117. Epub 2017 Apr 10.

17.

pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.

Allana S, Shashkina E, Mathema B, Bablishvili N, Tukvadze N, Shah NS, Kempker RR, Blumberg HM, Moodley P, Mlisana K, Brust JC, Gandhi NR.

Emerg Infect Dis. 2017 Mar;23(3):491-495. doi: 10.3201/eid2303.161034.

18.

Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.

Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, Mlisana K, Allana S, Campbell A, Mthiyane T, Morris N, Mpangase P, van der Meulen H, Omar SV, Brown TS, Narechania A, Shaskina E, Kapwata T, Kreiswirth B, Gandhi NR.

N Engl J Med. 2017 Jan 19;376(3):243-253. doi: 10.1056/NEJMoa1604544.

19.

More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Brust JC, Shah NS, Gandhi NR.

N Engl J Med. 2016 Dec 29;375(26):2610. doi: 10.1056/NEJMc1613123. No abstract available.

20.

IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis.

Auld SC, Lee SH, Click ES, Miramontes R, Day CL, Gandhi NR, Heilig CM.

Ann Am Thorac Soc. 2016 Dec;13(12):2151-2158.

Supplemental Content

Loading ...
Support Center